| Patient | Ernest Shackleton |
|---|---|
| Date of birth | 1874-02-15 |
| Identifiers | MRN HR-EX001-SYN-TD; SSN (made up) 000-01-7763 |
| Document date | 1921-07-21 |
| Author | Cormac Ellingsworth-Daly, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Ten-week review, three weeks after a coronary stent. [S]
Mr. Shackleton returns three weeks after coronary angiography, at which a drug-eluting stent was placed in the proximal left anterior descending artery through the right wrist, with no complications; he went home the same day. He has had no chest tightness since, even on the stairs with a load, and has not needed nitroglycerin. The wrist bruise has faded. He takes aspirin and clopidogrel every day and has had no bleeding beyond easy bruising on his forearms. He has not smoked for nine weeks. He drinks on four or five evenings a week, usually two drinks, sometimes three at dinners. He is impatient to get fit for the voyage. [S]
| Element | Detail |
|---|---|
| Angina | None since the stent |
| Access site | Right wrist healed |
| Antiplatelets | Aspirin and clopidogrel daily; minor bruising only |
| Tobacco | Not smoked for nine weeks |
| Alcohol | Two, sometimes three, drinks on four or five evenings a week |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations, or swelling |
| Hematologic | Positive | Easy bruising on the forearms; no nosebleeds, black stools, or blood in the urine |
| Musculoskeletal | Negative | No muscle aches |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release tablet, one tablet by mouth daily | once daily | Oral route | 1921-05-12 | active | S |
| Atorvastatin 80 mg tablet, one tablet by mouth daily | once daily | Oral route | 1921-05-12 | active | S |
| Metoprolol succinate extended-release 50 mg tablet, one tablet by mouth daily | once daily | Oral route | 1921-05-12 to 1921-05-26 | stopped | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue for chest pain, repeat every 5 minutes up to 3 doses | as needed for chest pain, up to 3 doses | Sublingual route | 1921-05-12 | active | S |
| Varenicline 1 mg tablet, one tablet by mouth twice a day after a one-week starter titration | twice a day after titration | Oral route | 1921-05-12 | active | S |
| Metoprolol succinate extended-release 100 mg tablet, one tablet by mouth daily | once daily | Oral route | 1921-05-26 | active | S |
| Clopidogrel 75 mg tablet, one tablet by mouth daily for six months after the stent (600 mg loading dose before the procedure) | once daily for six months | Oral route | 1921-07-01 | active | S |
| Ezetimibe 10 mg tablet, one tablet by mouth daily | once daily | Oral route | 1921-07-21 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1921-07-21 | Body height | 175 | cm | S |
| 1921-07-21 | Body weight | 84.4 | kg | S |
| 1921-07-21 | Body mass index (BMI) [Ratio] | 27.6 | kg/m2 | S |
| 1921-07-21 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1921-07-21 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1921-07-21 | Heart rate | 58 | /min | S |
| 1921-07-21 | Respiratory rate | 14 | /min | S |
| 1921-07-21 | Body temperature | 36.7 | Cel | S |
| 1921-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1921-07-21 | Cholesterol [Mass/volume] in Serum or Plasma | 128 | mg/dL | <=199 mg/dL | Normal | S |
| 1921-07-21 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 | mg/dL | >=40 mg/dL | Normal | S |
| 1921-07-21 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 62 | mg/dL | Below 100 for the general population; below 55 is his treatment target | Normal | S |
| 1921-07-21 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 1921-07-21 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-52 U/L | Normal | S |
| 1921-07-21 | Total score [AUDIT-C] | 4 | {score} | S |
Vital signs recorded on 1921-07-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 124/78, pulse 58, weight 84.4 kg |
| Cardiovascular | Regular rhythm; no murmur; right radial pulse normal; access site healed |
| Skin | Two small bruises on the forearms |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chest tightness and breathlessness on exertion for about three months, brought on by stairs, carrying loads, and walking fast in cold wind and relieved within minutes by rest, never at rest; resting ECG normal; cause not yet established at intake; coronary CT angiography and cardiology consultation requested | resolved | confirmed | R07.89 | S — Synthetic presenting problem anchored to his documented exertional breathlessness; superseded by the diagnosis at the cardiology consultation. |
| Nicotine dependence, cigarettes: about 25 a day since 16 (about 39 pack-years) | active | confirmed | F17.210 | S — Synthetic modern coding anchored to his documented heavy smoking. |
| Chronic coronary disease with stable exertional angina: 80% stenosis of the proximal left anterior descending artery with CT-FFR 0.70, mild right coronary artery disease, coronary calcium score 210, and normal left ventricular function; synthetic modern episode linked to his documented exertional illnesses and the coronary atheroma recorded at his death | active | confirmed | I25.118 | S — Synthetic modern diagnosis made at the cardiology consultation; Macklin's coronary diagnosis is recorded in CLM-0009 and the alternative theories as R. |
| Hyperlipidemia: LDL cholesterol 168 mg/dL and HDL 38 mg/dL at intake | active | confirmed | E78.5 | S — Synthetic modern risk factor; no historical measurement exists. |
| Prediabetes: HbA1c 5.9% at intake | active | confirmed | R73.03 | S — Synthetic modern risk factor; no historical measurement exists. |
| Drug-eluting stent in the proximal left anterior descending artery, placed for angina that persisted on medical therapy; dual antiplatelet therapy for six months | active | confirmed | Z95.5 | S — Synthetic status after the modern procedure. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (target below 130/80 mmHg) | Every visit | Completed today | 124/78 mmHg, at target |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 84.4 kg; walking daily |
| Examination | Angina frequency and Canadian Cardiovascular Society class, nitroglycerin use | Every visit | Completed today | No angina since the stent; no nitroglycerin |
| Medication safety | Dual antiplatelet therapy: adherence and bleeding | Every visit during dual therapy | Completed today | Both taken daily; minor bruising only; no NSAIDs |
| Medication safety | Adherence review: aspirin (or dual antiplatelet therapy), high-intensity statin, beta-blocker for angina | Every visit | Completed today | Atorvastatin, metoprolol, and both antiplatelets taken daily |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing lipid therapy, then every 3 to 12 months | Completed today | LDL 62 mg/dL (63% reduction), above the target below 55; ezetimibe added |
| Laboratory | ALT on high-intensity statin | Baseline, then only with symptoms | Completed today | 31 U/L; drawn with the lipid panel |
| Imaging | Stress imaging, coronary CT angiography, echocardiography, or invasive angiography | Only for new or worsening symptoms or a change in function despite optimized therapy; no routine surveillance | Not indicated | Asymptomatic after the stent; no surveillance imaging |
| Self-management | Tobacco use and cessation support (varenicline with counseling) | Every visit | Completed today | Abstinent for nine weeks |
| Survey | Alcohol use (AUDIT-C) and brief intervention | Each visit until within limits | Completed today | AUDIT-C 4, at the threshold; brief intervention repeated |
| Referral | Cardiac rehabilitation referral | At diagnosis of stable angina, and after PCI | Referred | Referred today; first session next week. Protocol deviation: the referral was due at the diagnosis of stable angina at the consultation and was deferred for eight weeks while revascularization was decided. No harm is evident: he had no cardiac events and is angina-free. Corrective action: refer at diagnosis in future, whatever revascularization plan is pending |
| Laboratory | HbA1c for prediabetes | Every 3 to 6 months while lifestyle change is under way, then yearly | Due | At the pre-departure visit |
Goal progress:
Guideline basis: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (Virani SS, et al. Circulation 2023;148(9):e9-e119) (2023); 2024 ESC Guidelines for the management of chronic coronary syndromes (Vrints C, et al. Eur Heart J 2024;45(36):3415-3537) (2024); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018)
Follow-up: Preventive visit in three weeks. Pre-departure review in seven weeks with an exercise test, lipids, and HbA1c. Next scheduled visit 1921-08-11: periodic adult preventive visit. [S]